The US Food and Drug Administration (FDA) has approved the first adaptive deep brain stimulation (aDBS) system for Parkinson’s disease (PD) that self-adjusts therapy to individual brain activity ...
The activity of the detected microbes can be determined based on the amount of C-D bonds. Credit: Xiaowei Ge (Boston University) A new study reveals that entacapone, a drug used to treat Parkinson’s ...
Table 1. Percentage of patients decreasing daily levodopa dose by 4–6 weeks after entacapone initiation in Phase III clinical trials as grouped by baseline daily levodopa dose and presence of ...
The Parkinson's drug entacapone disrupts the gut microbiome by inducing iron deficiency, favoring the growth of potentially harmful bacteria like E. coli. Using advanced molecular techniques, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback